Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK1 | P53667 | 2/20 | 0.58 |
| ▸ | PIM1 | P11309 | 9/20 | 0.56 |
| ▸ | PIM2 | Q9P1W9 | 8/20 | 0.56 |
| ▸ | PIM3 | Q86V86 | 6/20 | 0.56 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.53 |
| ▸ | PDPK1 | O15530 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4208864 | 0.82 | KRAS (0.51) | LIMK1PIM1PIM2PIM3CLK4 | |
| SCHEMBL4207979 | 0.80 | PARP1 (0.53) | PIM1PIM2PIM3CLK4PDPK1 | |
| SCHEMBL4213078 | 0.80 | PIM1 (0.59) | PIM1PIM2PIM3CLK4ALDH1A1 | |
| SCHEMBL4219756 | 0.80 | PIM1 (0.53) | PIM1PIM2PIM3CLK4PDPK1 | |
| SCHEMBL4218616 | 0.77 | PIM1 (0.55) | PIM1PIM2PIM3CLK4PDPK1 | |
| SCHEMBL4208127 | 0.77 | LIMK1 (0.59) | LIMK1PIM1PIM2PIM3CLK4 | |
| SCHEMBL4208072 | 0.76 | PARP1 (0.57) | PIM1PIM2PIM3CLK4MAPT | |
| SCHEMBL24589833 | 0.74 | LIMK1 (0.60) | LIMK1PIM1PIM2PIM3CLK4 | |
| SCHEMBL19024703 | 0.74 | LIMK1 (0.72) | LIMK1PIM1PIM2PIM3 | |
| SCHEMBL19805138 | 0.74 | LIMK1 (0.56) | LIMK1PIM1PIM2PIM3CLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090030196-A1 | PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS | ABBOTT LABORATORIES (US) | 2009-01-29 | — | — | US | claimed |
| US-20090030196-A1 | PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS | ABBOTT LABORATORIES (US) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030196-A1 | PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS | PIM1, PIM3, PIM2 | LIMK1 435/4885PIM1 1/4885PIM2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.